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Transcription is a complex process that relies on the cooperative interaction between sequence-specific factors and the basal transcription
machinery. The strength of a promoter depends on upstream or downstream cis-acting DNA elements, which bind transcription factors. In this
study, we investigated whether DNA elements located downstream of the JCV late promoter, encompassing the late leader peptide region, which
encodes agnoprotein, play regulatory roles in the JCV lytic cycle. For this purpose, the entire coding region of the leader peptide was deleted and
the functional consequences of this deletion were analyzed. We found that viral gene expression and replication were drastically reduced. Gene
expression also decreased from a leader peptide point mutant but to a lesser extent. This suggested that the leader peptide region of JCV might
contain critical cis-acting DNA elements to which transcription factors bind and regulate viral gene expression and replication. We analyzed the
entire coding region of the late leader peptide by a footprinting assay and identified three major regions (region I, II and III) that were protected by
nuclear proteins. Further investigation of the first two protected regions by band shift assays revealed a new band that appeared in new infection
cycles, suggesting that viral infection induces new factors that interact with the late leader peptide region of JCV. Analysis of the effect of the
leader peptide region on the promoter activity of JCV by transfection assays demonstrated that this region has a positive and negative effect on the
large T antigen (LT-Ag)-mediated activation of the viral early and late promoters, respectively. Furthermore, a partial deletion analysis of the leader
peptide region encompassing the protected regions I and II demonstrated a significant down-regulation of viral gene expression and replication.
More importantly, these results were similar to that obtained from a complete deletion of the late leader peptide region, indicating the critical
importance of these two protected regions in JCV regulation. Altogether, these findings suggest that the late leader peptide region contains
important regulatory elements to which transcription factors bind and contribute to the JCV gene regulation and replication.
© 2006 Elsevier Inc. All rights reserved.Keywords: JC virus; Transcription; ReplicationIntroduction
JCV is a human polyomavirus with a double-stranded
covalently linked circular DNA genome and is the etiological
agent of the fatal demyelinating disease, progressive multifocal
leukoencephalopathy (PML) in immunocompromised people⁎ Corresponding author. Fax: +1 215 204 0679.
E-mail address: msafak@temple.edu (M. Safak).
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doi:10.1016/j.virol.2006.01.025(Berger and Concha, 1995). The viral genome is composed of
regulatory and coding regions. The regulatory region contains
the promoter/enhancer elements that have been shown to be
targets for both viral and cellular transcription factors including
NF-κB (Ranganathan and Khalili, 1993; Safak et al., 1999a),
Tst-1 (Renner et al., 1994; Wegner et al., 1993), NF-1
(Amemiya et al., 1989, 1992), Sp-1 (Henson et al., 1992),
GBP-i (Raj and Khalili, 1994), YB-1 (Chen et al., 1995; Kerr et
al., 1994; Safak and Khalili, 2001; Safak et al., 1999b, 1999c,
2002), AP-1 (Kim et al., 2003; Sadowska et al., 2003), Purα
(Chen et al., 1995; Safak et al., 1999b) and Tat (Chowdhury et
67I. Akan et al. / Virology 349 (2006) 66–78al., 1990; Tada et al., 1990). The viral early coding region
encodes two regulatory proteins, large T antigen (LT-Ag) and
small t antigen (Sm t-Ag) (Frisque and White, 1992). LT-Ag
was shown to be a multifunctional phosphoprotein involved in
both viral DNA replication (Lynch and Frisque, 1990, 1991;
Lynch et al., 1994; Tavis and Frisque, 1991) and viral gene
transcription (Khalili et al., 1987; Lashgari et al., 1989). LT-Ag
is also an oncogenic protein, and its expression can lead to the
induction of tumors of neuronal origin in experimental animals
(Krynska et al., 1999; Small et al., 1986; Varakis et al., 1978).
Little is known about the function of JCV Sm t-Ag. However,
functional studies with SV40 Sm t-Ag indicate that it plays a
role in viral infection cycle and enhances the ability of LT-Ag to
transform cells (Chen and Hahn, 2003; Gaillard et al., 2001;
Nunbhakdi-Craig et al., 2003; Porras et al., 1996, 1999; Zhao et
al., 2003). It was shown that transgenic animals created with
wild-type SV40 genome developed tumors in different tissues,
however, those created with a Sm t-Ag deletion mutant of SV40
exhibited tumors almost exclusively occurring in highly mitotic
tissues such as lymphoid organs, suggesting that Sm t-Ag may
contribute significantly to tumor induction by LT-Ag in
nonproliferative tissues (Carbone et al., 1989; Choi et al.,
1988). This tumorigenic potential of Sm t-Ag is linked to the
inhibition of protein phosphatase 2A (PP2A, an abundant
family of serine/threonine phosphatases) (Ali and DeCaprio,
2001; Rundell and Parakati, 2001; Sontag et al., 1993). In
addition, several growth-promoting pathways were also found
to be altered in the Sm t-Ag expressing cells (Nunbhakdi-Craig
et al., 2003; Sontag et al., 1993, 1997; Zhao et al., 2003)
including activation of phosphotidylinositol (PI) 3-kinase
(Sontag et al., 1997), protein kinase Cζ (PKCζ) (Sontag et al.,
1997) and mitogen-activated protein kinase (Sontag et al.,
1993). In addition to Sm t-Ag and LT-Ag, the viral early coding
region encodes several spliced variants of early proteins (called
T's) which were shown to differentially interact with the
retinoblastoma family of tumor suppressor proteins (Trow-
bridge and Frisque, 1995). The viral late coding region encodes
structural capsid proteins (VP1, VP2 and VP3) and a basic
protein, agnoprotein, which has been recently shown to play
regulatory roles in viral DNA replication and transcription
(Safak et al., 2001, 2002). Recent analysis of JCVearly and late
gene expression by siRNA technology supports the above
observations regarding the function of agnoprotein (Orba et al.,
2004; Radhakrishnan et al., 2004). This protein was also shown
to have inhibitory effects on cell cycle progression (Darbinyan
et al., 2002) and be involved in negative regulation of DNA
repair by modulating Ku70 and Ku80 activity (Darbinyan et al.,
2004). Furthermore, it was recently reported that agnoprotein
interacts with cellular proteins, FEZ1 and HP1 alpha, and may
promote the transport of virions from nucleus to the cytoplasm
(Okada et al., 2005) and thereby facilitate the propagation of
JCV (Suzuki et al., 2005).
The coding regions of JCV show high degree of sequence
homology to that of the human BK virus (BKV) and simian
polyomavirus (SV40) (∼70%). However, the regulatory region
of each virus has highly divergent DNA sequences. This
divergence appears to play a determining role in the uniquepattern of expression of each virus in different cell types and/or
tissues (Frisque and White, 1992; Major and Ault, 1995). In
addition, JCV exhibits an unusually narrow tissue tropism
compared to SV40 and other polyomaviruses (Feigenbaum et
al., 1987; Kenney et al., 1984; Tada et al., 1989) in that it
lytically infects oligodendrocytes in the central nervous system
(Padgett et al., 1971) and causes a demyelinating disease known
as PML. JCV is a slow growing virus compared to SV40. It
takes several weeks to grow in tissue culture compared to 2 to 3
days for SV40. This virus also exhibits marked divergence from
SV40 with respect to the mode of viral entry into the cells. SV40
was reported to enter cells through a caveola-dependent
endocytosis pathway (Anderson et al., 1996; Stang et al.,
1997), but JCV follows a clathrin-dependent receptor-mediated
endocytosis pathway (Pho et al., 2000) in this process.
Additionally, a recent report indicates that serotonin receptors
may play an important role in JCV infection (Elphick et al.,
2004).
The promoter/enhancer elements of each polyomavirus have
a unique configuration. For example, the JCV Mad-1 strain
contains a two 98-bp tandem repeat, each of which is composed
of a TATA box and cis-acting enhancer elements. These
elements were previously shown to be the target for a number of
transcription factors (Raj and Khalili, 1995). In addition to the
tandem repeats, the upstream regions of the early and late
promoters of JCV also contain additional DNA elements which
are also target for transcription factors (Gallia et al., 1997; Kim
et al., 2003; Raj and Khalili, 1995; Raj et al., 1996).
Transcription factors bind to enhancer elements and communi-
cate with the basal transcriptional machinery which is
assembled around the TATA box by a mechanism that is
thought to involve DNA looping (Bondarenko et al., 2003;
Wagner et al., 2001). A prime example of such a regulation is
seen in the developmental regulation of the human β-globin
gene locus (Bulger and Groudine, 1999; Rippe et al., 1995).
The regulation of human and monkey polyomaviruses is not
fully understood but is thought to take place at multiple levels
including transcription and posttranscription. For instance,
SV40 early transcripts are targeted for cleavage posttranscrip-
tionally by microRNAs mapped to the untranslated region 3′ to
the polyadenylation cleavage site in the pre-mRNA sequences
of LT-Ag. By reducing expression of LT-Ag, it is thought that
the infected cells become less sensitive to LT-Ag-specific
cytotoxic cells. This may be a mechanism whereby the virus
evades host immunity (Sullivan et al., 2005). JCV and BKV
genomes also contain such potential DNA elements to encode
putative microRNAs, suggesting that their LT-Ag transcripts are
also subject to such a regulation. These findings suggest that
polyomaviruses contain regulatory elements outside of the
previously defined control regions. As such, we examined
whether or not DNA elements located downstream of the JCV
Mad-1 late promoter, namely, the late leader peptide region,
which corresponds to the agnoprotein-coding region, play a role
in JCV gene expression and replication. Our results suggest that
this region indeed contains important regulatory elements to
which transcription factors bind and contribute to the JCV gene
regulation and replication.
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Effect of a deletion mutant of the late leader peptide region on
JCV gene expression
We sought to investigate the role of downstream
sequences of the JCV late promoter in viral gene expression.
To do this, a region encompassing nucleotides 277 to 480 of
Mad-1 was deleted from the viral genome by a PCR-based
technique as described under Materials and methods (Fig.
1A). Note that the major splice donor site for the late
transcripts remained intact after the deletion (Shishido-Hara
et al., 2000). WT and Del mutant genomes were then
introduced into SVG-A cells by transfection, and nuclear
extracts were prepared at 7 days, 14 days and 21 days
posttransfection from transfectants and analyzed by Western
blotting to determine the level of both early and late gene
expression. As shown in Fig. 1B, the expression of VP1
from WT was readily detectable at 7 days, 14 days and 21
days posttransfection (lanes 2–4). Under similar conditions,
LT-Ag is only readily detectable at 21 days posttransfection.
In contrast, for the Del mutant, we observed an undetectable
level of expression for LT-Ag (lanes 5–7) and a little
expression for VP1 only at 21 days posttransfection (lane 7).
In parallel, we also compared the expression levels of LT-Ag
and VP1 from a Pt mutant, which removes the agnoprotein start
codon (Pt) so that agnoprotein is not produced, with that of WT
(Fig. 1D). The expression levels of both proteins were
negatively affected by the absence of the agnoprotein
production but not to the level that was observed for the Del
mutant. These results suggested that the late leader peptide
region of JCV may play regulatory roles in JCV gene
expression. It is possible that this region contains important
cis-acting DNA elements, to which transcription factors bind
and contribute to JCV gene expression. Figs. 1C and E
demonstrate the absence of agnoprotein expression from both
Del and Pt mutant viruses, respectively.
Effect of the deletion of the late leader peptide region on viral
DNA replication
Expression studies showed that the deletion of 277–480 bp
region negatively affected the viral early and late gene
expression (Figs. 1B and D). We reasoned that this should
also have functional consequences on viral DNA replication
because JCV DNA replication is dependent on the presence of
LT-Ag (Frisque and White, 1992). Therefore, in the next series
of experiments, we examined the effect of the Del mutant on
JCV DNA replication by employing a DpnI replication assay.
Mad-1 WT or Mad-1 Del mutant genome was transfected into
SVG-A cells using lipofectin, and low-molecular-weight DNA
was isolated at 7 days, 14 days and 21 days posttransfection
(Ziegler et al., 2004), and, subsequently, newly replicated DNA
was analyzed by Southern blotting following digestion with
DpnI which cuts only input (transfected) DNA. As shown in
Fig. 1F, deletion of the late leader peptide region significantly
impaired the replication of the mutant virus compared to WT(compare lanes 5–7 to 2–4) which is consistent with the results
from expression studies (Fig. 1B), where we found that
expression levels of viral proteins were substantially down-
regulated from the Del mutant genome compared to WT. We
also investigated the replication properties of a Pt mutant with
respect to WTand found that Pt mutant replicates less efficiently
than WT (Fig. 1G, compare lanes 5–7 to 2–4) but more
efficiently than the Del mutant, suggesting that the late leader
peptide region is critical for JCV replication.
Distinct regions within the late leader peptide region of JCV
were protected by nuclear proteins
Impaired gene expression and replication of the Del mutant
suggested the possibility that the 277–480 bp region of JCV
may contain cis-acting regulatory elements to which cellular
transcription factors bind and regulate JCV transcription. In
order to investigate this possibility, we performed a DNase I
footprinting assay. Nuclear extracts were prepared from both
infected and uninfected SVG-A cells, mixed with the
radiolabeled 277–480 bp fragment and incubated at 4 °C for
1 h. The samples were then subjected to a limited DNAse I
digestion and analyzed by autoradiography as described in
Materials and methods. As shown in Fig. 2, the footprinting
profile of the region showed three distinct protected regions,
designated as regions I, II and III (lanes 6 and 7) when we used
nuclear extracts from both uninfected and infected cells. The
footprinting pattern of the leader peptide region did not change
significantly when extracts from infected versus uninfected
cells were used, although some enhancement was observed in
the protected regions when extracts from infected cells were
used. Nonetheless, these results support our assumption that the
late leader peptide region of JCV contains cis-acting regulatory
elements to which transcription factors bind and regulate JCV
life cycle.
Infection cycle-specific nuclear complexes interact with
protected regions I and II
To further analyze the region encompassing the protected
regions I and II, we employed a band shift assay. For this,
nuclear extracts prepared from SVG-A cells, either uninfected
or infected with JCV Mad-1 strain, were incubated with the
radiolabeled probe, and DNA–protein complexes were ana-
lyzed by gel electrophoresis under nondenaturing conditions.
As shown in Fig. 3A, a major (band a) and a minor band (band
c) were formed when the nuclear proteins prepared from
uninfected (lane 2) cells were incubated with radiolabeled
probe. However, we observed the formation of a new additional
band (band b) with extracts prepared from infected cells (lanes 3
and 4), indicating that one or more infection cycle-induced
proteins also interact with this region.
To examine the specificity of the interaction of nuclear
proteins with this region, we performed a competitive band shift
assay (Fig. 3B). The unlabeled oligonucleotide inhibited the
ability of the nuclear proteins to bind to the radiolabeled
probe (lanes 3 and 4), whereas a nonspecific unlabeled
Fig. 1. Expression and replication properties of JCV Mad-1 WT and its deletion (Del) and point (Pt) mutant genomes. (A) Structural organization of JCV Mad-1
WT regulatory and agnoprotein-coding region. The corresponding regions for Del and Pt mutants are also depicted. The positions of the NF-κB motif (κB),
origin of viral DNA replication (ori), the two 98-tandem repeats and the agnoprotein-coding region are depicted. The direction of the expression of early (E) and
late (L) genes is indicated by the arrows. In Pt mutant, CATG nucleotides were substituted with TCGA so that the ATG start codon on WT was destroyed. (B−E)
Analysis of viral early (LT-Ag) and late (VP1, agnoprotein) proteins by Western blotting for WT, Del and Pt mutants. SVG-A cells were transfected with either
WT, Del or Pt genomes as described in Materials and methods. Nuclear (B and D) and whole cell (C and E) extracts were prepared at 7, 14 and 21 days
posttransfection and analyzed by Western blotting using an anti-agnoprotein polyclonal antibody (C and E), an anti-VP1 monoclonal antibody (pAB597) (B and
D, lower panel) and an anti-JCV LT-Ag (Ab 2000) monoclonal antibody (B and D, upper panel) as indicated. In lane 1 (B−E, each panel), extracts from
untransfected cells were loaded as negative control. Tfxn: transfection. (F and G) Effect of Del (F) and Pt (G) mutant on viral replication. SVG-A cells were
transfected with either Mad-1 WT genome, its Del or Pt mutants (8 μg/2 × 106 cells/75 cm2 flask) using lipofectin as described in Materials and methods. At 7
days, 14 days and 21 days posttransfection, low-molecular-weight DNA was isolated by a Qiagen spin columns (Ziegler et al., 2004), digested with BamHI and
DpnI enzymes, resolved on a 0.8% agarose gel and analyzed by Southern blotting using probes prepared from the entire Mad-1 genome. In lane 1 in each panel,
Mad-1 WT genome (2 ng) digested with BamHI was loaded as a positive control. Representative data are shown here. Input DNA (transfected) is indicated by a
bracket, and replicated DNA is indicated by an arrow.
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failed to inhibit the binding activity of nuclear complexes to
the same probe, confirming that specific nuclear complexes
interact with a specific region of the leader peptide region of
JCV.Effect of the late leader peptide region on LT-antigen-mediated
regulation of JCV early and late promoters
Previous studies have shown that LT-Ag is a potent activator
of the JCV late promoter (Chowdhury et al., 1990; Kim et al.,
Fig. 2. Several regions are protected by nuclear proteins in the leader peptide
region of JCV. Nuclear extracts (50 μg/lane) prepared from either SVG-A
uninfected (Uninf., lane 6) or infected cells (Inf., lane 7) were incubated with
probe (100,000 cpm/lane) as described in Materials and methods at 4 °C for 1 h.
Probe–protein complexes were subjected to a limited digestion with DNase I for
2 min, and reaction was stopped. Samples were extracted by phenol/chloroform
and analyzed on a 6% polyacrylamide gel followed by autoradiography. In lane
1, bacteriophage λDNAwas loaded as a marker after digesting withHindIII and
labeling with [32P]-ATP. In lane 2, undigested probe alone was loaded to
demonstrate its integrity. In lanes 3 and 4, probe was chemically sequenced
either with formic acid (lane 3) or combination of piperidine and formic acid
(lane 4) to partially determine the sequence of the probe. In lane 5, bovine serum
albumin (BSA, 50 μg/lane) was used in a DNase I reaction as a control to
demonstrate the interaction of a nonspecific protein with the probe. The
numbering on the figure is according to JCV Mad-1 strain.
70 I. Akan et al. / Virology 349 (2006) 66–782003; Safak et al., 2001). We next sought to investigate whether
the late leader peptide region has an effect on LT-Ag-mediated
regulation of JCV promoters in reporter gene assays. For this
purpose, we have subcloned the regulatory region of JCV,
containing the leader peptide region, into a CAT reportervector in the early and late orientation. Similarly, two different
deletion mutants of the leader peptide region were also
inserted separately into a CAT reporter vector as shown in Fig.
4A. Each reporter plasmid was then transfected into U-87MG
cells alone or in combination with an LT-Ag expression
plasmid, and the reporter activity of each plasmid was
determined 2 days after transfection. LT-Ag showed no
considerable effect on the early promoter activity when we
used a construct that does not contain the leader peptide
region (Fig. 4B, compare lane 4 to 5 and 6, respectively).
However, LT-Ag activated (∼2.6-fold) JCV early promoter
significantly when the construct used contained the leader
peptide region (compare lane 1 to 2 and 3, respectively). This
suggests that the leader peptide region is critical for LT-Ag-
mediated activation of the viral early promoter. Even the basal
activity of the promoter that contains the leader peptide region
was higher than that of the promoter that lacks this region
(Del-CAT), again emphasizing the importance of this region
in JCV gene regulation (compare lane 1 to lane 4). In
addition, a deletion construct that lacks the protected regions I
and II (Del-430-CAT) was also used in reporter gene assays
(lanes 7–9). This construct displayed a phenotype that is
similar to one that was observed for a larger deletion construct
(Del-CAT, lanes 4–5), although we observed a comparatively
modest stimulatory effect of LT-Ag on this promoter (Del-
430-CAT). These results suggest that LT-Ag-mediated effect
on the viral early promoter is largely due to the 431–480 bp
region of the leader peptide, which encompasses the protected
regions I and II.
In parallel, we also assayed the effect of the leader peptide
region and its deletion mutants on the activity of JCV late
promoter. LT-Ag strongly activated the transcription from the
viral late promoter that lacks the leader peptide region in a
dose-dependent manner (Fig. 4C, lanes 5 and 6, ∼2.6 and
∼5.7-fold, respectively). However, we did not observe such a
high level of LT-Ag-mediated activation from a reporter
construct that either possessed full-length leader peptide
region (lanes 1–3) or partially deleted version of the region
(lanes 7–9). These results indicate that the leader peptide
region inhibits LT-Ag-mediated activation of the viral late
promoter. Additionally, since WT and Del-430 constructs still
maintained agnoprotein start codon, there was a possibility
that the late transcripts may have had a bi-cistronic structure
so that, when the ribosome scans the message, it would
preferentially get the translation of agnoprotein but not the
downstream ORF, encoding CAT. This would then affect the
outcome of the experimental setting. In order to investigate
this possibility, we have reconstructed the reporter plasmids
for WT and Del-430 by mutating ATG start codon for
agnoprotein and repeated the CAT assays. Our results showed
no difference between the construct with or without the use of
ATG codon, suggesting that the difference observed between
WT and Del-430 or WT and Del reporters does not appear to
be due to the presence of agnoprotein start codon in the
constructs but rather a critical effect of the leader peptide
region on the LT-Ag-mediated transcription of the late
promoter (see Supplementary data).
Fig. 3. Nuclear complexes specifically interact with protected regions I and II of JCV in band shift assays. (A) Band shift assay. Band shift assays were carried out as
described previously (Ansari et al., 2001; Kim et al., 2003; Schreiber et al., 1989). Briefly, a double-stranded oligonucleotide spanning nt 451 to 480 of JCV genome
(40,000 cpm/lane) was end-labeled and incubated with nuclear extracts (10 μg/lane) prepared from SVG-A cells either uninfected (lane 2) or infected with JCVMad-1
strain (lanes 3 and 4). DNA–protein complexes were resolved on a 6% polyacrylamide gel under nondenaturing conditions and analyzed by autoradiography. Ifxn:
infection, d: day. (B) Competitive band shift assay. Probe plus nuclear extract from infected cells was also incubated either with unlabeled Mad-1 451–480 bp region
(WT) (lanes 3 and 4) or an unrelated oligonucleotide NF-κB (lanes 5 and 6) competitor (25- and 150-fold molar excess, respectively). Probe plus nuclear extract from
infected cells was also incubated alone (lane 2). DNA–protein complexes were analyzed as described above. In panels A and B, DNA–protein complexes are indicated
by the labeled arrows. Lane 1 in each panel contains probe alone. Comp.: competitor., NF-κB: double stranded oligonucleotide (5′-TCGACAGAGGGGACTTTCC-
GAGAGGC-3′).
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We further investigated the importance of the protected
regions by deletion analysis. For this, the region, encompassing
the protected region I and region II, was deleted from the viral
genome, and the effect of this deletion was analyzed by DpnI
assay. Mad-1 WT, Pt mutant, Del mutant or Del-430 Mut
genome was transfected separately into SVG-A cells, and low-
molecular-weight DNA was isolated by Qiagen spin columns
(Ziegler et al., 2004) at indicated time points and analyzed by
Southern blotting (Fig. 5A). As expected, the level of replicated
DNA for WT substantially increased by 21 days posttransfec-
tion (lane 4). In contrast, we only detected a very low level of
replicated DNA for both Del (lanes 5–7) and Del-430 (lanes 8–
10) mutants at 7 days, 14 days and even 21 days posttransfec-
tion. We also compared the relative replication efficiency of a Pt
mutant with both the deletion mutants and WT, respectively. Pt
mutant showed relatively strong replication efficiency at 21
days posttransfection compared to the deletion mutants
(compare lane 13 to lanes 7 and 10, respectively). However,
this mutant, replicated less efficiently compared to WT
(compare lanes 12 and 13 to 3 and 4, respectively). These
results demonstrate that 431–480 bp region is important for
JCV replication.
In parallel, we also analyzed the viral gene expression for
WT and mutants (Fig. 5B). Nuclear extracts prepared from
transfectants at indicated time points were analyzed for VP1expression by immunoprecipitation followed by Western
blotting. The level of VP1 expression for Del-430 mutant was
substantially decreased compared to WT. Even the expression
level of VP1 for Del-430 was undetectable by Western blotting
at 21 days posttransfection (lane 9, lower panel), which is
consistent with our findings from replication assays where we
observed that Del-430 exhibits slightly higher level of
replication at 14 days over 21 days posttransfection (A,
compare lane 9 to 10). In agreement with our findings from
replication assays (Figs. 1G and 5A), Pt mutant showed a
significantly higher level of VP1 expression, but less than WT
as measured by Western blotting (Fig. 5B, upper panel).
Additionally, to correlate the level of viral protein expression
with that of viral mRNA expression, we analyzed VP1
transcripts generated from the late promoter by Northern
blotting. As shown in Fig. 5C, the expression level of VP1
for both Pt mutant and WT was significantly increased by 21
days posttransfection (lanes 3 and 5, respectively), and, as
expected, the level of expression for Pt mutant was several fold
less than WT (compare lane 3 to 5). We also observed a
detectable level of expression of VP1 for Del mutant but
substantially less than both Pt mutant and WT (compare lane 9
to 3 and 5, respectively). However, under similar conditions, the
expression level of Del-430 mutant was undetectable, although
we observed a trace amount of signal for it at the longer
exposure time. These results correlate with the viral protein
expression studies from Fig. 5B and suggest that the observed
level of viral gene regulation for WT and its mutants appears to
Fig. 4. Effect of the leader peptide region on viral early and late gene expression in transient transfection assays. (A) The regulatory sequences of JCV Mad-1 shown
here were separately subcloned into pBLCAT3 reporter plasmid into BamHI site in the early (E) and late (L) orientation and used in transient transfection assays. (B and
C) Effect of leader peptide region (WT) and its deletion mutants (Del and Del-430) on LT-Ag-mediated viral early and late gene expression. Reporter plasmids depicted
in panel A were transiently transfected into U-87MG cells by the calcium phosphate precipitation method (Graham, 1973; Kim et al., 2003) either alone or in
combination with a JCV LT-Ag expression plasmid. At 48 h posttransfection, cells were harvested and CAT enzymatic activity or each transfectant was determined by
using equal 100-μg amounts of protein for each sample. Plasmid concentrations used in each transfection experiment are indicated at the bottom of the panel (in
micrograms per 60-mm diameter plate). Transfections were repeated several times with different plasmid preparations. Data in each panel were presented as “relative
CAT activity”, which is the basal level of expression of WT relative to the other experimental data points. Error bars indicate the standard deviation for each sample.
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from transcription studies (Fig. 5C) are consistent with our
observations from replication (Fig. 5A) and protein analysis
(Fig. 5B) data and emphasize again the critical importance of
the 431–480 bp region in JCV regulation.
In this communication, we have investigated the impor-
tance of the JCV late leader peptide region for viral geneexpression and replication by a deletion analysis and
demonstrated that this region contains cis-acting regulatory
elements to which cellular factors bind and contribute to JCV
regulation. Footprinting analysis of the late leader peptide
region showed several regions that were protected by nuclear
proteins. Subsequent analysis of a region encompassing the
protected regions I and II by band shift assays revealed an
73I. Akan et al. / Virology 349 (2006) 66–78infection cycle-dependent appearance of a new protein–DNA
complex (Fig. 3A, lanes 3 and 4). These results suggest that
infection cycle induces new factors that are capable of
interacting with a specific area located within the late leader
peptide region of JCV. Although what kinds of factors are
present within this complex is unknown, it is quite possible
that the new factors take part in the regulation of JCV gene
expression and replication by DNA looping. Nuclear com-
plexes that interact with specific regions present within the
late leader peptide area can be brought into the close
proximity of the RNA polymerase complex, which is
assembled around TATA box regions of the regulatory
elements of JCV, and may then directly or indirectly interact
with the transcriptional machinery and contribute to the viral
gene regulation or replication. In order to investigate this
hypothesis, we first analyzed the contribution of the late
leader peptide region to JCV regulation by reporter gene
assays. It was surprising to observe that LT-Ag activates JCV
early promoter when the late leader peptide region is present
in the promoter–reporter construct (Fig. 4B). JCV LT-Ag does
not activate the viral early promoter in constructs that do not
contain the late leader sequence (Safak et al., 1999c). In
addition, elimination of the protected regions I and II from the
viral early promoter in transient transfection assays resulted in
a considerable negative effect on LT-Ag-mediated activation
of the early promoter, suggesting that the protein complexes
which interact with the protected regions I and II are critical
for the LT-Ag-mediated activation of the viral early promoter.
It was also surprising that JCV late promoter which contains
the leader peptide region was not as responsive to LT-Ag-
mediated activation as the one that does not contain the leader
peptide region (Fig. 4C). This suggests that the leader peptide
region plays a restrictive role in the LT-Ag-mediated
activation of viral late promoter. However, it was previously
shown that LT-Ag is a strong activator of the viral late
promoter (Lashgari et al., 1989; Safak et al., 1999c). One
possible explanation for this differential regulation by LT-Ag
is that, in previous work, a much shorter fragment of the JCV
late promoter, which does not contain the leader peptide
region, was used, but, in the present work, the reporter
construct contains the leader peptide region. We also analyzed
the effect of deletion of a region encompassing the protected
regions I and II (431–480 bp region) on JCV regulation. This
deletion mutant virus showed a phenotype similar to the
larger deletion of the leader peptide region (277–480 bp
deletion) from the viral background. In both cases, the
replication activity of both mutants was significantly reduced
compared to WT. This finding suggests that the critical
regulatory elements of the leader peptide region lie in a
region that encompasses the protected regions I and II (Fig.
5A). This is consistent with the results from our in vitro
reporter gene assays (Fig. 4B) where a deletion mutant
construct, in which 431–480 bp region was deleted, was not
as responsive as WT to LT-Ag-mediated activation of the
early promoter. In conclusion, specific regions of the late
leader peptide of JCV contribute significantly to viral gene
regulation and replication through serving as target elementsto specific cellular factors. Experiments are currently
underway to identify these factors.
Materials and methods
Cell lines
SVG-A is a human glial cell line which was established by
transformation of human fetal glial cell line with an origin-
defective SV40 mutant and has been described previously
(Major et al., 1985). SVG-A cells were grown in Dulbecco's
Modified Eagle's Medium (DMEM) supplemented with 10%
heat-inactivated fetal bovine serum (FBS) and antibiotics
(penicillin/streptomycin, 100 μg/ml). They were maintained at
37 °C in a humidified atmosphere with 7% CO2. U-87MG
(ATCC HTB14) is a human glioblastoma cell line, which was
also maintained in culture as described for SVG-A.
Plasmid constructs
Reporter gene constructs containing the regulatory region of
JCV Mad-1 wild-type strain (WT) and agnoprotein-coding
region deletion mutants were created by PCR amplification as
described previously (Kim et al., 2003). Mad-1 (4989–480)
region was PCR-amplified using appropriate primers and was
inserted into BamHI site of pBLCAT3 vector in early (E) and
late (L) orientations. The resulting reporter plasmids were called
pBLCAT3-Mad-1 (4989–480) WT-E and pBLCAT3-Mad-1
(4989–480) WT-L. Similarly, agnoprotein deletion mutant
reporter plasmids, pBLCAT3-Mad-1 (4989–277) Del-E,
pBLCAT3-Mad-1 (4989–277) Del-L, pBLCAT3-Mad-1
(4989–430) Del-430-E and pBLCAT3-Mad-1 (4989–430)
Del-430-L, were also created by PCR amplification method
using appropriate primers. Amplified fragments were inserted
into BamHI site of pBLCAT3. pcDNA 3.1(+) LT-Ag expression
plasmid was created by PCR amplification of the LT-Ag-coding
region of Mad-1 (including intron) and was inserted into EcoRI/
XhoI sites of the vector. Agnoprotein deletion mutant viruses
Mad-1 (Δ277–480)-Agno-Del and Mad-1 (Δ431–480)-Agno-
Del were created as follows. Mad-1 (4556–980) fragment was
amplified by PCR using appropriate primers and inserted into
Bluescript KS (BstXI−/XhoI−) vector at SmaI site by blunt-end
ligation. The resulting plasmid was named Bluescript KS
(BstXI−/XhoI−)-Mad-1 (4556–980). This PCR-amplified frag-
ment contains an internal BstXI and anHpaI site. Mad-1 (4556–
277) and Mad-1 (481–980) fragments were also separately
amplified using PCR. Mad-1 (4556–277) and Mad-1 (481–
980) fragments were separately digested with (BstXI/XhoI) and
(XhoI/HpaI), respectively, and ligated together at XhoI site.
Finally, the ligation product was then inserted into BstXI/HpaI
sites of the Bluescript KS (BstXI−/XhoI−)-Mad-1 (4556–980)
plasmid, and the resulting plasmid was named Bluescript KS
(BstXI−/XhoI−)-Mad-1 (Δ277–480)-Agno-Del. Similarly, a
BstXI/HpaI fragment containing Δ431–480 deletion was also
inserted into BstXI/HpaI sites of Mad-1, and the new plasmid
was named Bluescript KS (BstXI−/XhoI−)-Mad-1 (Δ431–480)-
Agno-Del. The major splice donor site for the late transcripts
74 I. Akan et al. / Virology 349 (2006) 66–78was left intact (Shishido-Hara et al., 2000) in both plasmids
after the deletion manipulations. The information regarding the
primers that were used for PCR amplification is available upon
request. JCV Mad-1 point (Pt) mutant virus genome was kindly
provided by Dr. K. Nagashima, Japan. In the Pt mutant, the NcoI
site (CCATGG) of Mad-1 WT, containing the translation
initiation codon (ATG) of agnoprotein, was converted into XhoI
site (CTCGAG) by base substitution. Thus, the point mutantvirus does not express agnoprotein. The reporter plasmids that
do not contain ATG start codon for agnoprotein was also
constructed by PCR amplification. JCV Mad-1 Pt mutant virus
was used as a template for PCR amplification, where ATG
codon for agnoprotein was already altered. PCR products were
inserted into the BamHI site of pBLCAT3, and the resulting
plasmids were named pBLCAT3-Mad-1 (4989–480)-Agno-
ATGm-L and pBLCAT3-Mad-1 (4989–430)-Agno-ATGm-Del-
75I. Akan et al. / Virology 349 (2006) 66–78430-L. The integrity of the PCR-generated constructs was
confirmed by DNA sequencing. For the numbering on the
constructs, please refer to Figs. 1A, 4A and JCV Mad-1
sequence (Accession #: NC_001699).
Transfections, infection, cell extract preparations and Western
blotting
SVG-A cells (2 × 106 cell/75 cm2 flask) were transfected
with Mad-1 WT, Mad-1 point (Pt), Mad-1 (Δ277–480)
deletion (Del) mutant or Mad-1 (Δ431–480) Del mutant
(8 μg each) DNA using lipofectin according to manufac-
turer's recommendations (Invitrogen, Carlsbad, CA). At 5 h
posttransfection, cells were washed twice with PBS and fed
with DMEM supplemented with 2% FBS. Infection of SVG-
A cells with JCV Mad-1 strain was described previously
(Safak et al., 2002). Infection cycles were terminated at
various time points for protein extract preparation. Nuclear
extracts from untransfected or transfected cells were prepared
as described by Schreiber et al. (1989), and whole cell lysates
from untransfected or transfected cells were prepared as
described previously (Safak et al., 2002). Whole cell lysates
were analyzed by Western blotting, using an anti-agnoprotein
polyclonal antibody as described previously (Sadowska et al.,
2003). In parallel, nuclear extracts were analyzed for VP1 and
LT-Ag by Western blotting utilizing a monoclonal anti-VP-1
antibody (PAB 597) (a kind gift from Dr. W. Atwood, Brown
University, Rhode Island) and a monoclonal anti-SV40 LT-Ag
antibody (Ab-2), which is cross-reactive with JCV LT-Ag,
respectively.
Replication assay
Replication assays were carried out as previously described
(Safak et al., 2001). Briefly, SVG-A cells (2 × 106 cell/75 cm2
flask) were transfected with Mad-1 WT, Mad-1 point (Pt),
Mad-1 (Δ277–480) deletion (Del) mutant or Mad-1 (Δ431–
480) Del mutant (8 μg each) using lipofectin. Cells were
washed at 5 h posttransfection with phosphate-buffered saline
and fed with DMEM supplemented with 2% FBS. At indicated
time points, low-molecular-weight DNA containing both input
and replicated viral DNA was isolated using Qiagen spin
columns (Ziegler et al., 2004), digested with BamHI and DpnIFig. 5. Transcription and replication properties of WT and the mutants of the lead
replication. SVG-A cells were transfected with either WT, Del, Pt or Del-430
methods. Low-molecular-weight DNA was isolated at 7 days, 14 days and 21 days
with BamHI and DpnI enzymes, resolved on a 0.8% agarose gel and analyzed by
lane 1, Mad-1 WT genome (2 ng) digested with BamHI was loaded as a positive
indicated by a bracket and replicated DNA by an arrow. (B) Comparison of WT
In parallel to the replication studies, nuclear extracts were prepared from transfec
was subjected to immunoprecipitation using an anti-VP1 antibody (1.5 μg, pAB59
indicated. The heavy chain of the antibody (IgG), which was used in immunoprec
arrow. Tfxn: transfection. (C) (Top) Northern blot analysis of VP1 message in i
VP1, total RNA (30 μg of RNA/lane) was prepared from uninfected (lane 1) a
analyzed by Northern blotting for the detection of the VP1 transcripts. An arrow
from both uninfected (lane 1) and infected cells (lanes 2 to 9) by ethidium brom
RNA analyzed for the VP1 message. (Bottom) Analysis of the same blot for a ho
loading control.enzymes, resolved on 1% agarose gel and analyzed by
Southern blotting.
Northern blotting
Northern blotting was carried out as previously described
(Safak et al., 2002). Briefly, SVG-A cells (2 × 106 cell/75 cm2
flask) were transfected with Mad-1WT, Mad-1 point (Pt), Mad-1
(Δ277–480) deletion (Del) mutant or Mad-1 (Δ431–480) Del
mutant (8 μg each) using lipofectin. Total RNAwas isolated from
transfectants at specific time points as indicated on the respective
figure legend, fractionated on a 1% agarose gel and transferred
onto a nitrocellulose membrane. A PCR fragment corresponding
to a partial coding region of VP1 (JCV Mad-1 1570–2470 bp
region) was used as a probe to detect VP1 message.
DNase I footprinting assay
The coding region of agnoprotein was PCR-amplified using
the following primers: 5′-primer: 5′-ATTCCT GGATTC
ATGGTTCTTCGCCAGCTGTCA-3′ and 3′-primer: 5′-ATT-
CCTGAATTCTTACCTATGTAGCTTTTGGTT-3′ contain re-
striction sites for BamHI and EcoRI, respectively (the respective
restriction sites are underlined). PCR product was radiolabeled
with [γ-32P]-ATP on both ends by T4 polynucleotide kinase and
digested with BamHI to remove 3′-end labeling. A small portion
of the labeled probe was chemically sequenced using piperidine
or piperidine–formic acid combination to cut at G or G+A
residues, respectively (Ausubel et al., 1989). Nuclear extracts
(50 μg/reaction) prepared from either uninfected SVG-A or
SVG-A cells infected with JCV Mad-1 were incubated with
labeled probe (100,000 cpm/reaction) in a binding buffer
(100 mM KCl, 20 mM MgCl, 40 mM Tris–HCL [pH 8.0] and
0.2 mM EDTA) in 200 μl reaction volume at 4 °C for 1 h.
Subsequently, the reaction mixture was subjected to a limited
DNase I (Boehringer Mannheim) digestion at 37 °C for 2 min.
The reaction was stopped by the addition of 200 μl of stop buffer
(0.1 M EDTA, 0.6 M Na-acetate, 20 mg/ml salmon sperm
DNA). Finally, samples were extracted with phenol/chloroform
mixture and precipitated with ethanol. Equal amount of
radioactivity (10,000 cpm/lane) for each sample was fraction-
ated on a 6% polyacrylamide gel under denaturing conditions
and analyzed by autoradiography.er peptide region of JCV. (A) Effect of Del, Del-430 and Pt mutants on viral
genomes (8 μg/2 × 106 cells/75 cm2 flask) as described in Materials and
posttransfection using a Qiagen spin columns (Ziegler et al., 2004), digested
Southern blotting using probes prepared from the entire Mad-1 genome. In
control. A representative of data is shown here. Input DNA (transfected) is
versus mutant (Pt, Del and Del-430) viruses with respect to gene expression.
tants at 7, 14 and 21 days posttransfection. A hundred microgram of extract
7) and subsequently analyzed by immunoblotting using the same antibody as
ipitation, was detected by secondary antibody and was indicated by a labeled
nfected cells. In parallel to Western blot analysis of the nuclear proteins for
nd infected cells (lanes 2 to 9) as described in Materials and methods and
points to hybridized VP1 message. (Middle) Analysis of total RNA prepared
ide staining. Both 18S and 28S rRNA bands indicate the integrity of total
usekeeping gene, glyceraldehydes-3-phospate dehydrogenase (GAPDH), for a
76 I. Akan et al. / Virology 349 (2006) 66–78Mobility band shift assay
Band shift assays were carried out as described previously
(Kim et al., 2003; Sadowska et al., 2003). Briefly, a double-
stranded synthetic oligonucleotide encompassing JCVMad-1 nt
451–480 region was end-labeled with [γ-32P] ATP using T4
polynucleotide kinase and gel-purified. Nuclear extracts (10 μg/
lane) prepared from SVG-A cells, untransfected or transfected
with a JCV genome, were incubated with labeled probe
(40,000 cpm/lane) in a binding buffer containing 1.0 μg poly
(dI–dC), 12 mm HEPES (pH 7.9), 4 mM Trish [pH 7.5], 60 mM
KCl, 5 mM MgCl2 and 1.0 mM DTT. The reaction mixture was
incubated at 4 °C for 45 min to allow assembly of DNA–protein
complexes. Experimental conditions for competitive band shift
assays are described under respective figure legends. The
complexes were resolved on a 6% polyacrylamide gel in 0.5×
TBE (1× TBE is 89 mM Tris–HCl [pH 8.0], 89 mM boric acid
and 2 mM EDTA [pH 8.0]). The gel was dried, and complexes
were detected by autoradiography.
Reporter gene assays
U-87MG cells were transiently transfected by the
calcium phosphate precipitation method (Graham, 1973)
with reporter constructs, alone or in combination with the
expression plasmids. Plasmid concentrations used in
transfections are indicated in the respective figure legends.
The total amount of DNA transfected into the cells was
normalized by using the respective empty vector. A
glycerol shock procedure was performed at 4 h post-
transfection, and the medium was replenished. At 48 h
posttransfection, cells were lysed by freeze–thaw cycles.
Cell debris was cleared, and chloramphenicol acetyltrans-
ferase (CAT) activity of supernatants was determined.
Transfections were repeated at least three times with
different plasmid preparations.
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